Literature DB >> 12354387

Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation.

Yves Delneste1, Giovanni Magistrelli, Jean Gauchat, Jean Haeuw, Jean Aubry, Kayo Nakamura, Naoko Kawakami-Honda, Liliane Goetsch, Tatsuya Sawamura, Jean Bonnefoy, Pascale Jeannin.   

Abstract

Some exogenous antigens, such as heat shock proteins or apoptotic bodies, gain access to the MHC class I processing pathway and initiate CTL responses, a process called cross-priming. To be efficient in vivo, this process requires endocytosis of the antigen by dendritic cells via receptors which remain unidentified. Here, we report that scavenger receptors are the main HSP binding structures on human dendritic cells and identify LOX-1 as one of these molecules. A neutralizing anti-LOX-1 mAb inhibits Hsp70 binding to dendritic cells and Hsp70-induced antigen cross-presentation. In vivo, to target LOX-1 with a tumor antigen using an anti-LOX-1 mAb induces antitumor immunity. Thus, the scavenger receptor LOX-1 is certainly a promising target for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12354387     DOI: 10.1016/s1074-7613(02)00388-6

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  152 in total

1.  Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.

Authors:  Eynav Klechevsky; Anne-Laure Flamar; Yanying Cao; Jean-Philippe Blanck; Maochang Liu; Amy O'Bar; Olivier Agouna-Deciat; Peter Klucar; Luann Thompson-Snipes; Sandra Zurawski; Yoram Reiter; A Karolina Palucka; Gerard Zurawski; Jacques Banchereau
Journal:  Blood       Date:  2010-06-07       Impact factor: 22.113

2.  Modulatory role of calreticulin as chaperokine for dendritic cell-based immunotherapy.

Authors:  A Bajor; S Tischer; C Figueiredo; M Wittmann; S Immenschuh; R Blasczyk; B Eiz-Vesper
Journal:  Clin Exp Immunol       Date:  2011-06-03       Impact factor: 4.330

Review 3.  Cross-presentation: dendritic cells and macrophages bite off more than they can chew!

Authors:  Sven Brode; Paul A Macary
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

4.  Essential role of CD91 in re-presentation of gp96-chaperoned peptides.

Authors:  Robert J Binder; Pramod K Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-08       Impact factor: 11.205

Review 5.  Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come.

Authors:  Ayesha Murshid; Jianlin Gong; Mary Ann Stevenson; Stuart K Calderwood
Journal:  Expert Rev Vaccines       Date:  2011-11       Impact factor: 5.217

6.  High efficiency CD91- and LOX-1-mediated re-presentation of gp96-chaperoned peptides by MHC II molecules.

Authors:  Toyoshi Matsutake; Tatsuya Sawamura; Pramod K Srivastava
Journal:  Cancer Immun       Date:  2010-08-02

7.  Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance.

Authors:  Dayuan Li; Amit R Patel; Alexander L Klibanov; Christopher M Kramer; Mirta Ruiz; Bum-Yong Kang; Jawahar L Mehta; George A Beller; David K Glover; Craig H Meyer
Journal:  Circ Cardiovasc Imaging       Date:  2010-05-04       Impact factor: 7.792

8.  Checks and balances: the ocular response to infection.

Authors:  Michelle C Callegan
Journal:  Virulence       Date:  2010 Jul-Aug       Impact factor: 5.882

9.  CD204 suppresses large heat shock protein-facilitated priming of tumor antigen gp100-specific T cells and chaperone vaccine activity against mouse melanoma.

Authors:  Jie Qian; Huanfa Yi; Chunqing Guo; Xiaofei Yu; Daming Zuo; Xing Chen; John M Kane; Elizabeth A Repasky; John R Subjeck; Xiang-Yang Wang
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

Review 10.  Chaperokine-induced signal transduction pathways.

Authors:  Alexzander Asea
Journal:  Exerc Immunol Rev       Date:  2003       Impact factor: 6.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.